Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA And Beijing-based RDPAC Call For Innovative Medicines To Support China’s Healthcare Reform

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The Pharmaceutical Research and Manufacturers of America and the Beijing-based R&D Pharmaceutical Association Committee that represents Big Pharma in China, recently submitted a paper to the Chinese government to help the government better understand the role of innovative medicines in the ongoing healthcare reform in China

You may also be interested in...



China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

One-third of small generic drug makers will be filtered out of the market in the next three to five years by the implementation of the new system, market research firm estimates.

China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

One-third of small generic drug makers will be filtered out of the market in the next three to five years by the implementation of the new system, market research firm estimates.

China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D

SHANGHAI - China's essential drug system will hasten the consolidation of the generic industry while a measure for drug pricing will encourage innovation, according to a Frost & Sullivan report on the impact of China's healthcare reform, released May 18

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel